Update on osteoporosis treatment

被引：35

作者：

Nogues, Xavier ^{[1
,2
,3
]}

Martinez-Laguna, Daniel ^{[2
,3
,4
,5
]}

机构：

[1] Hosp del Mar, Inst Hosp Mar Invest Med, Serv Med Interna, URFOA Unidad Invest Musculoesquelet, Barcelona, Spain

[2] Inst Carlos III, CIBER Fragilidad & Envejecimiento Saludable CIBER, Madrid, Spain

[3] Univ Autonoma Barcelona, Barcelona, Spain

[4] Inst Catala Salut, Atencio Primaria Barcelona Ciutat, Barcelona, Spain

[5] Inst Univ Invest Atenc Primaria Jordi Gol, Grp Invest GREMPAL, Barcelona, Spain

来源：

MEDICINA CLINICA | 2018年 / 150卷 / 12期

关键词：

Osteoporosis; Treatment; Fragility fractures; Secondary prevention; BONE-MINERAL DENSITY; VERTEBRAL FRACTURE RISK; POSTMENOPAUSAL WOMEN; ZOLEDRONIC ACID; HIP FRACTURE; ATRIAL-FIBRILLATION; POSITION STATEMENT; CLINICAL FRACTURES; AMERICAN-COLLEGE; RANDOMIZED-TRIAL;

D O I：

10.1016/j.medcli.2017.10.019

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment of osteoporosis should be directed primarily towards secondary prevention of fractures. The occurrence of drug-related adverse effects for the treatment of osteoporosis has led to a reevaluation of the indications, the duration of treatment and even withdrawal of some drugs from the market. This review has been made from different patient profiles that practitioners will find in usual practice; from patients with hip fracture with cognitive impairment, limitation of their day-to-day living activities and comorbidities, to active patients without any limitations; patients with vertebral fractures and non vertebral fractures where secondary prevention is highly important. In general, antiresorptive drugs (alendronate and risedronate) will be the first choice. Zoledronate or denosumab will be indicated in cases of digestive intolerance, poor adherence or an increased risk of hip fracture. Teriparatide will be indicated to patients with 2 or more previous vertebral fractures or very low bone density. (C) 2017 Elsevier Espana, S.L.U. All rights reserved.

引用

页码：479 / 486

页数：8

共 60 条

[1] Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research [J].

Adler, Robert A. ;

El-Hajj Fuleihan, Ghada ;

Bauer, Douglas C. ;

Camacho, Pauline M. ;

Clarke, Bart L. ;

Clines, Gregory A. ;

Compston, Juliet E. ;

Drake, Matthew T. ;

Edwards, Beatrice J. ;

Favus, Murray J. ;

Greenspan, Susan L. ;

McKinney, Ross, Jr. ;

Pignolo, Robert J. ;

Sellmeyer, Deborah E. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2016, 31 (01) :16-35

[2] OSTEOPOROSIS [J].

ALBRIGHT, F .

ANNALS OF INTERNAL MEDICINE, 1947, 27 (06) :861-882

[3] Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement [J].

Anagnostis, Panagiotis ;

Paschou, Stavroula A. ;

Mintziori, Gesthimani ;

Ceausu, Iuliana ;

Depypere, Herman ;

Lambrinoudaki, Irene ;

Mueck, Alfred ;

Perez-Lopez, Faustino R. ;

Rees, Margaret ;

Senturk, Levent M. ;

Simoncini, Tommaso ;

Stevenson, John C. ;

Stute, Petra ;

Tremollieres, Florence A. ;

Goulis, Dimitrios G. .

MATURITAS, 2017, 101 :23-30

[4] Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis [J].

Avenell, Alison ;

Gillespie, William J. ;

Gillespie, Lesley D. ;

O'Connell, Dianne .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (02)

[5] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].

Black, Dennis M. ;

Delmas, Pierre D. ;

Eastell, Richard ;

Reid, Ian R. ;

Boonen, Steven ;

Cauley, Jane A. ;

Cosman, Felicia ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Mautalen, Carlos ;

Mesenbrink, Peter ;

Hu, Huilin ;

Caminis, John ;

Tong, Karen ;

Rosario-Jansen, Theresa ;

Krasnow, Joel ;

Hue, Trisha F. ;

Sellmeyer, Deborah ;

Eriksen, Erik Fink ;

Cummings, Steven R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822

[6] Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial [J].

Black, DM ;

Thompson, DE ;

Bauer, DC ;

Ensrud, K ;

Musliner, T ;

Hochberg, MC ;

Nevitt, MC ;

Suryawanshi, S ;

Cummings, SR .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (11) :4118-4124

[7] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].

Black, DM ;

Cummings, SR ;

Karpf, DB ;

Cauley, JA ;

Thompson, DE ;

Nevitt, MC ;

Bauer, DC ;

Genant, HK ;

Haskell, WL ;

Marcus, R ;

Ott, SM ;

Torner, JC ;

Quandt, SA ;

Reiss, TF ;

Ensrud, KE .

LANCET, 1996, 348 (9041) :1535-1541

[8] Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency [J].

Bolland, Mark J. ;

Grey, Andrew .

BMJ-BRITISH MEDICAL JOURNAL, 2016, 354

[9] 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension [J].

Bone, Henry G. ;

Wagman, Rachel B. ;

Brandi, Maria L. ;

Brown, Jacques P. ;

Chapurlat, Roland ;

Cummings, Steven R. ;

Czerwinski, Edward ;

Fahrleitner-Pammer, Astrid ;

Kendler, David L. ;

Lippuner, Kurt ;

Reginster, Jean-Yves ;

Roux, Christian ;

Malouf, Jorge ;

Bradley, Michelle N. ;

Daizadeh, Nadia S. ;

Wang, Andrea ;

Dakin, Paula ;

Pannacciulli, Nicola ;

Dempster, David W. ;

Papapoulos, Socrates .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07) :513-523

[10] Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass [J].

Bone, Henry G. ;

Bolognese, Michael A. ;

Yuen, Chui Kin ;

Kendler, David L. ;

Miller, Paul D. ;

Yang, Yu-Ching ;

Grazette, Luanda ;

San Martin, Javier ;

Gallagher, J. Christopher .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04) :972-980

← 1 2 3 4 5 6 →